A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Clinical trial NCT05575518 · UNKNOWN
Trial details
- NCT number
- NCT05575518
- Sponsor
- Stellah Mpagama
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-11
- Primary completion
- 2025-12-31
- Enrollment
- 414
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.